FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4315707314> ?p ?o ?g. }

• W4315707314 endingPage "e411" @default.
• W4315707314 startingPage "e411" @default.
• W4315707314 abstract "Objectives: Reduction in skeletal muscle mass is the most important component in the diagnosis of sarcopenia. Aging and chronic heart failure due to cardiovascular diseases (CVDs) accelerate the reduction in skeletal muscle. However, no effective drugs for sarcopenia are available. The purpose of this study was to explore the associations of prescribed medications with higher skeletal muscle mass in patients with CVD. Design and Methods: This was a single-center, retrospective, cross-sectional analysis. The subjects were 636 inpatients with CVD who had been taking prescribed medicines for at least 4 weeks at the time of admission. Prescription data were collected from electronic medical records database. Drugs and drug combinations were selected for analysis when they were prescribed to more than 10% (64 cases) of all subjects. Because of their frequent use in clinical practice for CVD, various combinations of angiotensin II receptor blockers (ARBs), beta-blockers, calcium channel blockers (CCBs), and statins were also examined. Skeletal muscle volume was assessed with a bioelectrical impedance assay. Results: The mean age was 73 ± 12 years (male, 54.4%). The body mass index and skeletal muscle index (SMI) were 23.8 ± 4.3 kg/m2 and 6.46 ± 1.42 kg/m2, respectively. ACC/AHA stage C/D heart failure was shown in 21.4%. Single regression analysis showed that SMI was positively associated with the use of CCBs, ARBs, statins, antihyperuricemic agents, dipeptidyl peptidase-4 (DPP-4) inhibitors, oral antidiabetic agents excluding DPP-4 inhibitors, ARB/CCB combination, statin/CCB combination, ARB/statin combination, and ARB/beta-blocker combination. Diuretics, antiarrhythmic agents, and anticoagulants were negatively associated with SMI. Stepwise multivariate regression analysis revealed that ARB/statin combination was independently and positively associated with SMI whereas diuretics and antiarrhythmic agents were independently and negatively associated with SMI. After adjustment using propensity score matching, SMI was significantly higher in ARB/statin combination users than in non-users. Conclusion: Combination use of an ARB and a statin was associated with a higher SMI in patients with CVD. A future randomized, controlled trial is warranted to determine whether the ARB/statin combination will increase the SMI and prevent sarcopenia in CVD patients. The results of the present study may be useful for drug repositioning to screen for drug candidates." @default.
• W4315707314 created "2023-01-12" @default.
• W4315707314 creator A5019621072 @default.
• W4315707314 creator A5047880957 @default.
• W4315707314 creator A5080334664 @default.
• W4315707314 creator A5083477395 @default.
• W4315707314 creator A5089152707 @default.
• W4315707314 date "2023-01-01" @default.
• W4315707314 modified "2023-10-03" @default.
• W4315707314 title "PS-C25-1: ANGIOTENSIN II RECEPTOR BLOCKER AND STATIN COMBINATION THERAPY ASSOCIATED WITH HIGHER SKELETAL MUSCLE INDEX IN PATIENTS WITH CARDIOVASCULAR DISEASE" @default.
• W4315707314 doi "https://doi.org/10.1097/01.hjh.0000917028.47073.75" @default.
• W4315707314 hasPublicationYear "2023" @default.
• W4315707314 type Work @default.
• W4315707314 citedByCount "0" @default.
• W4315707314 crossrefType "journal-article" @default.
• W4315707314 hasAuthorship W4315707314A5019621072 @default.
• W4315707314 hasAuthorship W4315707314A5047880957 @default.
• W4315707314 hasAuthorship W4315707314A5080334664 @default.
• W4315707314 hasAuthorship W4315707314A5083477395 @default.
• W4315707314 hasAuthorship W4315707314A5089152707 @default.
• W4315707314 hasBestOaLocation W43157073141 @default.
• W4315707314 hasConcept C126322002 @default.
• W4315707314 hasConcept C164705383 @default.
• W4315707314 hasConcept C2776214593 @default.
• W4315707314 hasConcept C2776839432 @default.
• W4315707314 hasConcept C2776999253 @default.
• W4315707314 hasConcept C2778198053 @default.
• W4315707314 hasConcept C2779959927 @default.
• W4315707314 hasConcept C2780221984 @default.
• W4315707314 hasConcept C33872192 @default.
• W4315707314 hasConcept C71924100 @default.
• W4315707314 hasConcept C98274493 @default.
• W4315707314 hasConceptScore W4315707314C126322002 @default.
• W4315707314 hasConceptScore W4315707314C164705383 @default.
• W4315707314 hasConceptScore W4315707314C2776214593 @default.
• W4315707314 hasConceptScore W4315707314C2776839432 @default.
• W4315707314 hasConceptScore W4315707314C2776999253 @default.
• W4315707314 hasConceptScore W4315707314C2778198053 @default.
• W4315707314 hasConceptScore W4315707314C2779959927 @default.
• W4315707314 hasConceptScore W4315707314C2780221984 @default.
• W4315707314 hasConceptScore W4315707314C33872192 @default.
• W4315707314 hasConceptScore W4315707314C71924100 @default.
• W4315707314 hasConceptScore W4315707314C98274493 @default.
• W4315707314 hasIssue "Suppl 1" @default.
• W4315707314 hasLocation W43157073141 @default.
• W4315707314 hasLocation W43157073142 @default.
• W4315707314 hasOpenAccess W4315707314 @default.
• W4315707314 hasPrimaryLocation W43157073141 @default.
• W4315707314 hasRelatedWork W2420010530 @default.
• W4315707314 hasRelatedWork W2507292359 @default.
• W4315707314 hasRelatedWork W2724378168 @default.
• W4315707314 hasRelatedWork W4221097959 @default.
• W4315707314 hasRelatedWork W4225287837 @default.
• W4315707314 hasRelatedWork W4280590099 @default.
• W4315707314 hasRelatedWork W4309912594 @default.
• W4315707314 hasRelatedWork W4311792334 @default.
• W4315707314 hasRelatedWork W4385174715 @default.
• W4315707314 hasRelatedWork W4385820157 @default.
• W4315707314 hasVolume "41" @default.
• W4315707314 isParatext "false" @default.
• W4315707314 isRetracted "false" @default.
• W4315707314 workType "article" @default.